SYNTHESIS & EVAL OF 1,5,6 TRIAZACHRYSENE & 5,6,11 TRIAZACHRYSENE DERIVATIVES

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 我们的主要研究兴趣是发现和开发新药。本课题组近年来一直致力于非喜树碱类拓扑异构酶I靶向抗肿瘤药物的设计与合成。已经鉴定了几种有效的拓扑异构酶I靶向剂。研究正在进行中，以确定这些化合物中更有前途的候选人发展到临床。最近，在我们的实验室进行了研究，以开发代理，将选择性地结合和稳定G-四链体DNA。我们目前正在探索这些G-四链体稳定剂在癌症化疗中的前景和全部潜力。此外，我们的研究小组已经开始研究发现新的先导化合物，用于开发同工酶特异性拓扑异构酶II靶向药物，用于未来开发这类癌症化疗药物中的改进临床药物。 更多信息请访问http://medchem.rutgers.edu/lavoie.shtml

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Our primary research interests are in the discovery and the development of novel pharmaceuticals. For several years our research group has focused on the design and synthesis of novel non-camptothecin topoisomerase I-targeting antitumor agents. Several potent topoisomerase I-targeting agents have been identified. Studies are in progress to identify among these compounds the more promising candidates for development into the clinic. Recently, studies in our laboratory have been undertaken to develop agents that will selectively bind and stabilize G-quadruplex DNA. We are presently exploring the promise and full potential of these G-quadruplex stabilizers in cancer chemotherapy. In addition, our research group has initiated research into the discovery of new lead compounds for the development of isozyme specific topoisomerase II-targeting agents for the future development of an improved clinical agent within this class of cancer chemotherapeutic agents. See more at http://medchem.rutgers.edu/lavoie.shtml